Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06417697
Status:
TERMINATED
Last Update Posted:
2024-05-16
First Post:
2024-05-08
Brief Title:
A Phase 1b Study to Evaluate the Safety of XEN-101
Sponsor:
Xeno Biosciences
Organization:
Xeno Biosciences
Study Overview
Official Title:
A Phase 1b Randomized Double-Blind Parallel Placebo-Controlled Study to Evaluate the Effects of XEN-101 on Safety Tolerability and Pharmacodynamics in Subjects with Obesity
Status:
TERMINATED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study not stopped for safety reasons Data were reviewed after the first 23 patients had completed scheduled dosing and there was no signal of efficacy for change in body weight This clinical trial has been determined to be futile
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
Detailed Description:
This study will assess the safety tolerability and weight loss associated with XEN-101 in obese men and women
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None